By Dean Giovanniello, RPh., Vice President; Rebecca Podolsky, Senior Analyst; Holger Müller, Vice President; Balazs Felcsuti, Vice President; and Carrie Jones, Vice President
- COVID-19 vaccines may not be available for at least 12 to 18 months, and possibly as long as five years. More near-term solutions are needed to provide a therapeutic treatment and to achieve prophylactic immunity in high-risk groups.
- Historical evidence from similar viruses such as SARS1 and the H1N1 influenza established precedents for the use of antibodies from convalescent patients to treat or confer immunity.
- As accuracy of and access to antibody-detecting diagnostics grow, allowing for widespread testing, countries have initiated nationwide serosurveys which may hold the key to develop plasma-derived antibody therapies.
- A significant number of companies and consortia have embarked on this concept and first-movers are entering clinical testing as early as in the second half of 2020.
- However, the availability of sufficient amounts of convalescent plasma remains a key challenge. A novel approach, called recombinant anti-coronavirus 19 hyperimmune gammaglobulin or rCIG, may provide a longer-term alternative to plasma-derived therapies and can generate scalable polyclonal antibody therapies for millions of patients.
Read the Blog Entry: https://healthadvancesblog.com/2020/05/13/protective-antibody-therapy-preventing-future-covid-19-outbreaks/